BibTex RIS Kaynak Göster

GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT

Yıl 2002, Cilt: 15 Sayı: 3, 180 - 182, 03.12.2016

Su Gülsün Berrak Ahmet Soysal Emine Türkkan Cengiz Canpolat

Öz

patient with metastatic Ewing's sarcoma who developed encephalopathy after treatment with gemcitabine, and his rapid recovery after discontinuation of the drug.
Key Words: Gemcitabine, Neurotoxicity, Pediatric cancer

Kaynakça

  • Pavlakis N, Bell DH, Millward MJ, et al. Ratal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997; 80: 286-291.
  • Green MR. Gemcitabine safety overview. Semin Oncol 1996; 23: S32-S35.
  • Gemzar product labeling. Indianapolis, IN, Eli Lilly and Company, March 1997.
  • Hinchey J, Chaves C, Appignani B, et al. /I reversible posterior leukoencephalopathy syndrome. N Eng! J Med 1996; 334: 494-500.
  • Ay H, Buonannao F, Schaefer F, et al. Posterior leukoencephalopathy without severe hypertension. Utility of diffusion- weighted MRI. Neurology 1998; 51: 1369- 1376.
  • Vaughn D, Jarvik J, Hackney D, el al. High- dose cytarabine neurotoxicity. MR findings during the acute phase. Am J Neuroradiol 1993; 14: 1014-1016.
  • Rontos HA, Wei EP, Deitrich D. Mechanism of cerebral arteriolar abnormalities after acute hypertension. Am J Physiol 1981; 240: 511- 527.
  • Oelanty N, Vaughan C, Frucht S, Stubgen P.
  • Erythropoe tin-associated hypertensive
  • posterior leukoencephalopathy. Neurology 1997; 49: 686-689.
  • lilion AD, Kallesen J, Cow! CT, et al. Ceftazidime-related nonconvulsive status epilepticus. Arch Intern Med 1994; 154: 586- 589.
  • Herishanu YO, Zlotnik M, Mostoslavsky M, et al. Cufuroxime-induced encephalopathy. Neurology 1998; 50: 1873-1875.
  • Jallon P, Fankhauser L, Du Pasquier R, Coeytaux A. Severe but reversible encephalopathy associated with cefepime. Neurophysiol Clin 2000; 30: 383-386.

Yıl 2002, Cilt: 15 Sayı: 3, 180 - 182, 03.12.2016

Su Gülsün Berrak Ahmet Soysal Emine Türkkan Cengiz Canpolat

Öz

Kaynakça

  • Pavlakis N, Bell DH, Millward MJ, et al. Ratal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997; 80: 286-291.
  • Green MR. Gemcitabine safety overview. Semin Oncol 1996; 23: S32-S35.
  • Gemzar product labeling. Indianapolis, IN, Eli Lilly and Company, March 1997.
  • Hinchey J, Chaves C, Appignani B, et al. /I reversible posterior leukoencephalopathy syndrome. N Eng! J Med 1996; 334: 494-500.
  • Ay H, Buonannao F, Schaefer F, et al. Posterior leukoencephalopathy without severe hypertension. Utility of diffusion- weighted MRI. Neurology 1998; 51: 1369- 1376.
  • Vaughn D, Jarvik J, Hackney D, el al. High- dose cytarabine neurotoxicity. MR findings during the acute phase. Am J Neuroradiol 1993; 14: 1014-1016.
  • Rontos HA, Wei EP, Deitrich D. Mechanism of cerebral arteriolar abnormalities after acute hypertension. Am J Physiol 1981; 240: 511- 527.
  • Oelanty N, Vaughan C, Frucht S, Stubgen P.
  • Erythropoe tin-associated hypertensive
  • posterior leukoencephalopathy. Neurology 1997; 49: 686-689.
  • lilion AD, Kallesen J, Cow! CT, et al. Ceftazidime-related nonconvulsive status epilepticus. Arch Intern Med 1994; 154: 586- 589.
  • Herishanu YO, Zlotnik M, Mostoslavsky M, et al. Cufuroxime-induced encephalopathy. Neurology 1998; 50: 1873-1875.
  • Jallon P, Fankhauser L, Du Pasquier R, Coeytaux A. Severe but reversible encephalopathy associated with cefepime. Neurophysiol Clin 2000; 30: 383-386.
Toplam 13 adet kaynakça vardır.

Ayrıntılar

Bölüm Case Reports
Yazarlar

Su Gülsün Berrak Bu kişi benim

Ahmet Soysal Bu kişi benim

Emine Türkkan Bu kişi benim

Cengiz Canpolat Bu kişi benim

Yayımlanma Tarihi 3 Aralık 2016
Yayımlandığı Sayı Yıl 2002 Cilt: 15 Sayı: 3

Kaynak Göster

APA Berrak, S. G., Soysal, A., Türkkan, E., Canpolat, C. (2016). GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT. Marmara Medical Journal, 15(3), 180-182.
AMA Berrak SG, Soysal A, Türkkan E, Canpolat C. GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT. Marmara Med J. Mart 2016;15(3):180-182.
Chicago Berrak, Su Gülsün, Ahmet Soysal, Emine Türkkan, ve Cengiz Canpolat. “GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT”. Marmara Medical Journal 15, sy. 3 (Mart 2016): 180-82.
EndNote Berrak SG, Soysal A, Türkkan E, Canpolat C (01 Mart 2016) GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT. Marmara Medical Journal 15 3 180–182.
IEEE S. G. Berrak, A. Soysal, E. Türkkan, ve C. Canpolat, “GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT”, Marmara Med J, c. 15, sy. 3, ss. 180–182, 2016.
ISNAD Berrak, Su Gülsün vd. “GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT”. Marmara Medical Journal 15/3 (Mart 2016), 180-182.
JAMA Berrak SG, Soysal A, Türkkan E, Canpolat C. GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT. Marmara Med J. 2016;15:180–182.
MLA Berrak, Su Gülsün vd. “GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT”. Marmara Medical Journal, c. 15, sy. 3, 2016, ss. 180-2.
Vancouver Berrak SG, Soysal A, Türkkan E, Canpolat C. GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT. Marmara Med J. 2016;15(3):180-2.